The relationship between serum magnesium level and coronary artery ectasia .

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
ahmed elghoribi ◽  
Manar Al Zaki ◽  
kamal mansour
2010 ◽  
Vol 13 (7) ◽  
pp. 335-339 ◽  
Author(s):  
S. Khani ◽  
M. Shokrzadeh ◽  
P.k Karamoddin ◽  
S. Shahmohamm

Author(s):  
Yonathan A. Suparman ◽  
Herlyani Khosama ◽  
Corry N. Mahama

Background: Magnesium has a central nervous system depressant effect by inhibiting the N-methyl-D-aspartate (NMDA) receptor, an antagonist of calcium channels, and increasing the surface tension of the cell membrane. Patients with epilepsy who had seizures more than 4 times/week had lower serum magnesium levels than those with the episode of less than or equal to 1 time/week. A low dose of magnesium added to phenytoin or carbamazepine can reduce seizure frequency. We want to evaluate the relationship between serum magnesium levels and their dietary intake level with seizure control in Manado.Methods: Patients with epilepsy aged 18-65 years, from July 2019 to October 2019, were tested for dietary and serum magnesium level in the last 30 days using NutriSurvey software. Regression models were used to quantify the relationship between dietary and serum magnesium level with seizure freedom and its frequency in the last 30 days.Results: One hundred and ten epileptic patients were included in this study. The median serum magnesium level is 2 mg/dl. There was no significant relationship between serum magnesium levels and seizure freedom (p=0.423) or its frequency in the last 30 days (p=0.966). Dietary magnesium intake (OR 1.01; 95% CI 1.00-1.02, p=0.034) was associated with seizure freedom but not with its frequency (p=0.423).Conclusions: Dietary magnesium intake was associated with seizure freedom, but serum magnesium levels were not associated with seizure freedom or frequency.


Medicine ◽  
2020 ◽  
Vol 99 (2) ◽  
pp. e18719
Author(s):  
Rending Zhu ◽  
Xiaolu He ◽  
Yanqun Du ◽  
Nan Chen ◽  
Wei Wang ◽  
...  

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0253592
Author(s):  
Mayumi Ito ◽  
Makoto Yamaguchi ◽  
Takayuki Katsuno ◽  
Hironobu Nobata ◽  
Shiho Iwagaitsu ◽  
...  

Background Several studies have revealed the relationship between serum magnesium levels and vascular calcification in chronic kidney disease patients. Despite excellent predictability of abdominal aorta calcification for cardiovascular disease events, the relationship between serum magnesium levels and abdominal aorta calcification, as evaluated by quantitative methods, in pre-dialysis patients remains unclear. This study aimed to determine the abdominal aorta calcification volume using computerized tomography and its association with serum magnesium levels in pre-dialysis chronic kidney disease stage 5 patients. Methods This single-center cross-sectional study included 100 consecutive patients with pre-dialysis chronic kidney disease stage 5 between January 2016 and May 2020 at Aichi Medical University Hospital, Japan. The relationships between serum magnesium levels and the abdominal aorta calcification volume were assessed using multiple linear regression models after adjusting for clinically relevant factors. We also assessed clinical factors that affect serum magnesium levels. Results The mean serum magnesium level was 2.0 mg/dL (interquartile range, 1.8 to 2.3). Multivariate analyses revealed that a higher serum magnesium level (stand. β = -0.245, p = 0.010) was significantly associated with a reduced abdominal aorta calcification volume, and that a history of cardiovascular disease (stand. β = 0.3792, p < 0.001) and older age (stand. β = 0.278, p = 0.007) were significantly associated with an increased abdominal aorta calcification volume. Moreover, multivariate analysis showed that the use of proton pump inhibitor or potassium-competitive acid blocker was significantly associated with lower serum magnesium levels (stand. β = -0.246, p = 0.019). Conclusions The present study revealed that the higher Mg level was significantly associated with lower volume of abdominal aorta calcification in pre-dialysis chronic kidney disease stage 5 patients. Further studies should be undertaken to determine the appropriate magnesium level to suppress vascular calcification.


2003 ◽  
Vol 145 (6) ◽  
pp. 1108-1113 ◽  
Author(s):  
John V Booth ◽  
Barbara Phillips-Bute ◽  
Charles B McCants ◽  
Mihai V Podgoreanu ◽  
Peter K Smith ◽  
...  

2017 ◽  
Vol 47 (2) ◽  
pp. 231 ◽  
Author(s):  
Goksel Cagirci ◽  
Selcuk Kucukseymen ◽  
Isa Oner Yuksel ◽  
Nermin Bayar ◽  
Erkan Koklu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document